Morphological and molecular changes following neoadjuvant endocrine therapy of ER positive breast cancer: implications for clinical practice.

Badr, Nahla M, Spooner, David, Steven, Jane, Stevens, Andrea and Shaaban, Abeer M (2021) Morphological and molecular changes following neoadjuvant endocrine therapy of ER positive breast cancer: implications for clinical practice. Histopathology. ISSN 1365-2559.

[img]
Preview
Text
Morphological and molecular changes following neoadjuvant endocrine therapy of ER positive breast cancer_ implications for clinical practice.pdf

Download (19MB) | Preview
Official URL: https://onlinelibrary.wiley.com/doi/10.1111/his.14...

Abstract

BACKGROUND

Neoadjuvant endocrine therapy (NAET) is used in the management of estrogen receptor positive (ER+) breast cancer. The optimal method for histological assessment of response and the effect of NAET on the tumour morphology, grade and molecular profile remain unclear.

MATERIAL AND METHODS

A single large institution cohort of 132 patients who received NAET over a 13-year period was identified. Comprehensive clinical, histopathological and follow up data were collected. A detailed histological review of a subset with residual post-treatment carcinoma was undertaken.

RESULTS

Two carcinomas (both of lobular type) achieved complete pathological response. Central scarring was seen in 49.3% of tumours post-treatment. Significant changes in tumour type (41.6%), grade (downgrading in a third of tumours), PR expression (22.3%) with a switch to PR negative status in 17.6% of cases were observed. The latter was associated with absence of tumour infiltrating lymphocytes (p=0.005). 10% of cases showed a change in HER2 expression (p=0.002). Median patient survival was 60 months and downgrading of tumours was associated with better overall survival (p=0.05).

CONCLUSIONS

We propose a histological method for assessment of residual carcinoma following NAET and recommend repeat ER/PR/HER2 testing to inform management and prognosis.

Item Type: Article
Subjects: QZ Pathology. Oncology
Divisions: Planned IP Care > Oncology and Clinical Haematology
Related URLs:
Depositing User: Mr Philip O'Reilly
Date Deposited: 20 Jan 2021 13:22
Last Modified: 20 Jan 2021 13:22
URI: http://www.repository.uhblibrary.co.uk/id/eprint/3866

Actions (login required)

View Item View Item